Drug–Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-Glycoprotein

被引:0
作者
Akihiro Ando
Shinichiro Sasago
Yoshihiro Ohzone
Yohei Miyamoto
机构
[1] Toray Industries,Pharmaceutical Clinical Research Department
[2] Inc.,Department of Bio Research
[3] Kamakura Techno-Science,ADME & Tox. Research Institute
[4] Inc.,undefined
[5] Sekisui Medical Co.,undefined
[6] Ltd.,undefined
来源
European Journal of Drug Metabolism and Pharmacokinetics | 2016年 / 41卷
关键词
Digoxin; Verapamil; Sodium Dihydrogen Phosphate; Organic Modifier Content; Uremic Pruritus;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:549 / 558
页数:9
相关论文
共 114 条
[1]  
Chan LM(2004)The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability Eur J Pharm Sci 21 25-51
[2]  
Lowes S(2009)Drug interactions at the blood–brain barrier: fact or fantasy? Pharmacol Ther 123 80-104
[3]  
Hirst BH(1988)Role of opioid receptors in bombesininduced grooming Ann N Y Acad Sci 525 291-300
[4]  
Eyal S(2011)Role of transporters in drug interactions Arch Pharm Res 34 1865-1877
[5]  
Hsiao P(2012)Nalfurafine hydrochloride for the treatment of pruritus Expert Opin Pharmacother 13 1507-1513
[6]  
Unadkat JD(1976)A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta 455 152-162
[7]  
Gmerek DE(2000)Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems Drug Metab Dispos 28 1238-1243
[8]  
Cowan A(1994)Identification of a human delta opioid receptor: cloning and expression Life Sci 54 463-469
[9]  
Han HK(2012)Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients Am J Nephrol 36 175-183
[10]  
Inui S(2010)Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study Nephrol Dial Transplant 25 1251-1257